Positives

• Patients using P21 describe a slow cumulative cognitive lift, with effects often becoming clear only after a month of consistent low dosing.
  
  
• One patient reported improved short-term memory and sustained focus emerging gradually over 4-6 weeks.
  
  

Negatives

• Patients sometimes report no perceptible effect at lower doses and frustration with the long onset window before judging response.
  
  
• A patient reported that the intranasal route was workable but messy and easy to misdose.
  
  

Hurdles & Side Effects

• Human clinical trial data is essentially absent; P21 remains a research compound with no FDA pathway.
  
  
• Patients are reliant on grey-market peptide vendors of variable quality, and intranasal compounding is not standardized.